Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of BMS-986504 to use safely in people with lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their tumors are missing the MTAP gene.
Researchers are assessing different doses of CHS-114 when combined with toripalimab in people with advanced digestive cancers. The people in this study have digestive cancers that have metastasized (spread) or are inoperable (cannot be surgically removed). These cancers include:
The purpose of this study is to find the best dose of ABBV-383 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called metastatic castration-resistant prostate cancers (mCRPC).
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
Mirdametinib blocks proteins called MEK1 and MEK2, which play an important role in cancer cell growth and survival. By blocking MEK1 and MEK2, mirdametinib may slow or stop the growth of your cancer.
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
Researchers are comparing two combination treatments for breast cancer that has metastasized (spread) or is inoperable (cannot be removed surgically). The people in this study have breast cancer that has hormone receptors (HR) but is negative for the HER2 protein.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
